In summary, the results of this study indicate that therapies targeting P2RX3 may be useful in treating CPP in women with a diverse range of painful etiologies, whereas women with active endometriosis could benefit from treatments targeting TRPV1, TRPA1, SCN9A, or SCN11A. This evidence concerns the gene SCN11A and central precocious puberty.